LifeSci Capital Reaffirms Buy Rating on Centessa Pharmaceuticals (CNTA) with a $39 PT, Anticipates Key Orexin Pipeline Data

Centessa Pharmaceuticals (NASDAQ:CNTA) is one of the best up and coming stocks with huge upside potential. On September 9, LifeSci Capital analyst Francois Brisebois reiterated a Buy rating on Centessa Pharmaceuticals and set a price target of $39.00.

In Q2 2025, Centessa Pharmaceuticals reported that the company had $404.1 million in cash and investments, which is projected to fund its operations into mid-2027. The company’s R&D expenses increased to $42.7 million in Q2 2025, up from $32.8 million in Q2 2024. This led to a wider net loss of $50.3 million in Q2 2025, compared to a net loss of $43.8 million in Q2 2024.

Centessa also provided updates on its orexin receptor 2 (OX2R) agonist pipeline. Its lead candidate, ORX750, is progressing in the Phase 2a CRYSTAL-1 study for the treatment of narcolepsy types 1 and 2 (NT1 and NT2) and idiopathic hypersomnia. Data from this study is anticipated within the year. Additionally, the Phase 1 trial for ORX142 began following the FDA’s clearance of its Investigational New Drug application in June 2025, with data expected within the year.

Centessa Pharmaceuticals (NASDAQ:CNTA) is a clinical-stage pharmaceutical company that discovers, develops, and delivers medicines.

While we acknowledge the potential of CNTA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.